Login Register Cart 0
Review Article

HuR作为癌症的治疗靶点：未来会怎样

卷 29, 期 1, 2022

发表于: 28 June, 2021

页: [56 - 65] 页: 10

弟呕挨: 10.2174/0929867328666210628143430

价格: $65

摘要

ELAV样蛋白1或HuR（人抗原R）是一种RNA结合蛋白，在人类中由ELAVL1基因编码，其最佳功能之一是稳定mRNA以调节基因表达。HuR蛋白过表达无疑与肿瘤生长，进展和转移的风险增加有关，使其成为癌症的潜在治疗靶点候选者。干扰HuR表达的新型药物已经在体外和体内进行了测试，并取得了有希望的结果。本文的目的是回顾现有文献中关于可以积极作用和抑制HuR表达的潜在因子。HuR分子控制各种原癌基因，细胞因子和生长因子的表达，是肿瘤进展，侵袭和转移的主要参与者，并构成癌症治疗的新兴靶标。对PubMed数据库进行了彻底搜索，并纳入了所有已发表的文章，这些文章提供了通过HuR抑制表现出抗肿瘤作用的分子的科学数据。根据这些数据，HuR抑制应该是癌症治疗中一个有希望的靶点。

关键词: HuR蛋白，癌症治疗，HuR抑制，小分子，miRNA，siRNA。

« Previous Next »
[1]
Lunde, B.M.; Moore, C.; Varani, G. RNA-binding proteins: Modular design for efficient function. Nat. Rev. Mol. Cell Biol., 2007, 8(6), 479-490.
[http://dx.doi.org/10.1038/nrm2178] [PMID: 17473849]
[2]
Hogan, D.J.; Riordan, D.P.; Gerber, A.P.; Herschlag, D.; Brown, P.O. Diverse RNA-binding proteins interact with functionally related sets of RNAs, suggesting an extensive regulatory system. PLoS Biol., 2008, 6(10)e255
[http://dx.doi.org/10.1371/journal.pbio.0060255] [PMID: 18959479]
[3]
Ma, W.J.; Chung, S.; Furneaux, H. The Elav-like proteins bind to AU-rich elements and to the poly(A) tail of mRNA. Nucleic Acids Res., 1997, 25(18), 3564-3569.
[http://dx.doi.org/10.1093/nar/25.18.3564] [PMID: 9278474]
[4]
Srikantan, S.; Gorospe, M. HuR function in disease. Front. Biosci.(Landmark Ed), 2012, 17, 189-205.
[http://dx.doi.org/10.2741/3921] [PMID: 22201738]
[5]
Kotta-Loizou, I.; Giaginis, C.; Theocharis, S. Clinical significance of hur expression in human malignancy. Med. Oncol., 2014, 31(9), 161.
[http://dx.doi.org/10.1007/s12032-014-0161-y]
[6]
Giaginis, C.; Alexandrou, P.; Delladetsima, I.; Karavokyros, I.; Danas, E.; Giagini, A.; Patsouris, E.; Theocharis, S. Clinical significance of hu-antigen receptor (hur) and cyclooxygenase-2 (cox-2) expression in human malignant and benign thyroid lesions. Pathol. Oncol. Res., 2016, 22(1), 189-196.
[http://dx.doi.org/10.1007/s12253-015-9997-5] [PMID: 26498465]
[7]
Giaginis, C.; Sampani, A.; Kotta-Loizou, I.; Giannopoulou, I.; Danas, E.; Politi, E.; Tsourouflis, G.; Kouraklis, G.; Patsouris, E.; Keramopoulos, A.; Nakopoulou, L.; Theocharis, S. Elevated hu-antigen receptor (hur) expression is associated with tumor aggressiveness and poor prognosis but not with cox-2 expression in invasive breast carcinoma patients. Pathol. Oncol. Res., 2018, 24(3), 631-640.
[http://dx.doi.org/10.1007/s12253-017-0288-1] [PMID: 28808873]
[8]
Giaginis, C.; Alexandrou, P.; Tsoukalas, N.; Sfiniadakis, I.; Kavantzas, N.; Agapitos, E.; Patsouris, E.; Theocharis, S. Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. Tumour Biol., 2015, 36(1), 315-327.
[http://dx.doi.org/10.1007/s13277-014-2637-y] [PMID: 25252849]
[9]
Yiakouvaki, A.; Dimitriou, M.; Karakasiliotis, I.; Eftychi, C.; Theocharis, S.; Kontoyiannis, D.L. Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J. Clin. Invest., 2012, 122(1), 48-61.
[http://dx.doi.org/10.1172/JCI45021] [PMID: 22201685]
[10]
Brauß, T.F.; Winslow, S.; Lampe, S.; Scholz, A.; Weigert, A.; Dehne, N.; von Stedingk, K.; Schmid, T.; Brüne, B. The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors. Mol. Carcinog., 2017, 56(12), 2620-2629.
[http://dx.doi.org/10.1002/mc.22706] [PMID: 28731284]
[11]
Peng, W.; Furuuchi, N.; Aslanukova, L.; Huang, Y-H.; Brown, S.Z.; Jiang, W.; Addya, S.; Vishwakarma, V.; Peters, E.; Brody, J.R.; Dixon, D.A.; Sawicki, J.A. Elevated hur in pancreas promotes a pancreatitis-like inflammatory microenvironment that facilitates tumor development. Mol. Cell. Biol., 2018, 38(3), e00427-e17.
[http://dx.doi.org/10.1128/MCB.00427-17] [PMID: 29133460]
[12]
Goldberg-Cohen, I.; Furneauxb, H.; Levy, A.P.A. A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J. Biol. Chem., 2002, 277(16), 13635-13640.
[http://dx.doi.org/10.1074/jbc.M108703200] [PMID: 11834731]
[13]
Holmes, B.; Benavides-Serrato, A.; Freeman, R.S.; Landon, K.A.; Bashir, T.; Nishimura, R.N.; Gera, J. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma. Oncogene, 2018, 37(6), 732-743.
[http://dx.doi.org/10.1038/onc.2017.360] [PMID: 29059166]
[14]
Kurosu, T.; Ohga, N.; Hida, Y.; Maishi, N.; Akiyama, K.; Kakuguchi, W.; Kuroshima, T.; Kondo, M.; Akino, T.; Totsuka, Y.; Shindoh, M.; Higashino, F.; Hida, K. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br. J. Cancer, 2011, 104(5), 819-829.
[http://dx.doi.org/10.1038/bjc.2011.20] [PMID: 21285980]
[15]
Kotta-Loizou, I.; Vasilopoulos, S.N.; Coutts, R.H.A.; Theocharis, S. Current evidence and future perspectives on hur and breast cancer development, prognosis, and treatment.Neoplasia; Neoplasia Press, Inc.: United States, 2016, pp. 674-688.
[16]
Levidou, G.; Kotta-Loizou, I.; Tasoulas, J.; Papadopoulos, T.; Theocharis, S. Clinical significance and biological role of hur in head and neck carcinomas. Dis. Markers, 2018, 20184020937
[http://dx.doi.org/10.1155/2018/4020937] [PMID: 29619127]
[17]
Guo, X.; Wu, Y.; Hartley, R.S. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol., 2009, 6(5), 575-583.
[http://dx.doi.org/10.4161/rna.6.5.10079] [PMID: 19875930]
[18]
Roff, A.N.; Craig, T.J.; August, A.; Stellato, C.; Ishmael, F.T. MicroRNA-570-3p regulates HuR and cytokine expression in airway epithelial cells. Am. J. Clin. Exp. Immunol., 2014, 3(2), 68-83.
[PMID: 25143867]
[19]
Guo, J.; Li, M.; Meng, X.; Sui, J.; Dou, L.; Tang, W.; Huang, X.; Man, Y.; Wang, S.; Li, J. MiR-291b-3p induces apoptosis in liver cell line NCTC1469 by reducing the level of RNA-binding protein HuR. Cell. Physiol. Biochem., 2014, 33(3), 810-822.
[http://dx.doi.org/10.1159/000358654] [PMID: 24685524]
[20]
Guo, X.; Connick, M.C.; Vanderhoof, J.; Ishak, M.A.; Hartley, R.S. MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int. J. Mol. Sci., 2015, 16(4), 7112-7132.
[http://dx.doi.org/10.3390/ijms16047112] [PMID: 25830480]
[21]
Abdelmohsen, K.; Kim, M.M.; Srikantan, S.; Mercken, E.M.; Brennan, S.E.; Wilson, G.M.; Cabo, Rd.; Gorospe, M. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle, 2010, 9(7), 1354-1359.
[http://dx.doi.org/10.4161/cc.9.7.11164] [PMID: 20305372]
[22]
Fan, X.C.; Steitz, J.A. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc. Natl. Acad. Sci. USA, 1998, 95(26), 15293-15298.
[http://dx.doi.org/10.1073/pnas.95.26.15293] [PMID: 9860962]
[23]
Gallouzi, I.E.; Brennan, C.M.; Steitz, J.A. Protein ligands mediate the CRM1-dependent export of HuR in response to heat shock. RNA, 2001, 7(9), 1348-1361.
[http://dx.doi.org/10.1017/S1355838201016089] [PMID: 11565755]
[24]
Rebane, A.; Aab, A.; Steitz, J.A. Transportins 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR. RNA, 2004, 10(4), 590-599.
[http://dx.doi.org/10.1261/rna.5224304] [PMID: 15037768]
[25]
Grammatikakis, I.; Abdelmohsen, K.; Gorospe, M. Posttranslational control of hur function.Wiley Interdisciplinary Reviews: RNA; Blackwell Publishing Ltd, 2017.
[26]
Zhu, Z.; Zhao, Y.; Li, J.; Tao, L.; Shi, P.; Wei, Z.; Sheng, X.; Shen, D.; Liu, Z.; Zhou, L.; Tian, C.; Fan, F.; Shen, C.; Zhu, P.; Wang, A.; Chen, W.; Zhao, Q.; Lu, Y. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Carcinog., 2016, 55(10), 1399-1410.
[http://dx.doi.org/10.1002/mc.22383] [PMID: 26310813]
[27]
Blanco, F.F.; Preet, R.; Aguado, A.; Vishwakarma, V.; Stevens, L.E.; Vyas, A.; Padhye, S.; Xu, L.; Weir, S.J.; Anant, S.; Meisner-Kober, N.; Brody, J.R.; Dixon, D.A. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7(45), 74043-74058.
[http://dx.doi.org/10.18632/oncotarget.12189] [PMID: 27677075]
[28]
Guo, J.; Lv, J.; Chang, S.; Chen, Z.; Lu, W.; Xu, C.; Liu, M.; Pang, X. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget, 2016, 7(29), 45249-45262.
[http://dx.doi.org/10.18632/oncotarget.9932] [PMID: 27303922]
[29]
Abdelmohsen, K.; Kuwano, Y.; Kim, H.H.; Gorospe, M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: Implications for cellular senescence. Biol. Chem., 2008, 389(3), 243-255.
[http://dx.doi.org/10.1515/BC.2008.022] [PMID: 18177264]
[30]
Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell, 2009, 136(2), 215-233.
[http://dx.doi.org/10.1016/j.cell.2009.01.002] [PMID: 19167326]
[31]
Meisner, N.C.; Filipowicz, W. Properties of the regulatory RNA-binding protein HuR and its role in controlling miRNA repression. Adv. Exp. Med. Biol., 2010, 700, 106-123.
[http://dx.doi.org/10.1007/978-1-4419-7823-3_10] [PMID: 21627034]
[32]
Muralidharan, R.; Babu, A.; Amreddy, N.; Srivastava, A.; Chen, A.; Zhao, Y.D.; Kompella, U.B.; Munshi, A.; Ramesh, R. Tumor-targeted nanoparticle delivery of hur sirna inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the rna-binding protein huR. Mol. Cancer Ther., 2017, 16(8), 1470-1486.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0134] [PMID: 28572169]
[33]
Wu, X.; Gardashova, G.; Lan, L.; Han, S.; Zhong, C.; Marquez, R.T.; Wei, L.; Wood, S.; Roy, S.; Gowthaman, R.; Karanicolas, J.; Gao, F.P.; Dixon, D.A.; Welch, D.R.; Li, L.; Ji, M.; Aubé, J.; Xu, L. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Commun. Biol., 2020, 3(1), 193.
[http://dx.doi.org/10.1038/s42003-020-0933-1] [PMID: 32332873]
[34]
D’Agostino, V.G.; Lal, P.; Mantelli, B.; Tiedje, C.; Zucal, C.; Thongon, N.; Gaestel, M.; Latorre, E.; Marinelli, L.; Seneci, P.; Amadio, M.; Provenzani, A. Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. Sci. Rep., 2015, 5, 16478.
[http://dx.doi.org/10.1038/srep16478] [PMID: 26553968]
[35]
Lee, C.Y.; Sher, H.F.; Chen, H.W.; Liu, C.C.; Chen, C.H.; Lin, C.S.; Yang, P.C.; Tsay, H.S.; Chen, J.J.W. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol. Cancer Ther., 2008, 7(11), 3527-3538.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-2288] [PMID: 19001436]
[36]
Kaur, K.; Wu, X.; Fields, J.K.; Johnson, D.K.; Lan, L.; Pratt, M.; Somoza, A.D.; Wang, C.C.C.; Karanicolas, J.; Oakley, B.R.; Xu, L.; De Guzman, R.N. The fungal natural product azaphilone-9 binds to HuR and inhibits HuR-RNA interaction in vitro. PLoS One, 2017, 12(4)e0175471
[http://dx.doi.org/10.1371/journal.pone.0175471] [PMID: 28414767]
[37]
Amreddy, N.; Babu, A.; Panneerselvam, J.; Srivastava, A.; Muralidharan, R.; Chen, A.; Zhao, Y.D.; Munshi, A.; Ramesh, R. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine (Lond.), 2018, 14(2), 373-384.
[http://dx.doi.org/10.1016/j.nano.2017.11.010] [PMID: 29155362]
[38]
Costantino, C.L.; Witkiewicz, A.K.; Kuwano, Y.; Cozzitorto, J.A.; Kennedy, E.P.; Dasgupta, A.; Keen, J.C.; Yeo, C.J.; Gorospe, M.; Brody, J.R. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res., 2009, 69(11), 4567-4572.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-0371] [PMID: 19487279]
[39]
Masaoutis, C.; Korkolopoulou, P.; Theocharis, S. Exosomes in sarcomas: Tiny messengers with broad implications in diagnosis, surveillance, prognosis and treatment. Cancer Lett., 2019, 449, 172-177.
[40]
Wang, W.; Yang, X.; Kawai, T.; López de Silanes, I.; Mazan-Mamczarz, K.; Chen, P.; Chook, Y.M.; Quensel, C.; Köhler, M.; Gorospe, M. AMP-activated protein kinase-regulated phosphorylation and acetylation of importin alpha1: Involvement in the nuclear import of RNA-binding protein HuR. J. Biol. Chem., 2004, 279(46), 48376-48388.
[http://dx.doi.org/10.1074/jbc.M409014200] [PMID: 15342649]
[41]
Martínez-Chantar, M.L.; Vázquez-Chantada, M.; Garnacho, M.; Latasa, M.U.; Varela-Rey, M.; Dotor, J.; Santamaria, M.; Martínez-Cruz, L.A.; Parada, L.A.; Lu, S.C.; Mato, J.M. S-adenosylmethionine regulates cytoplasmic HuR via AMP-activated kinase. Gastroenterology, 2006, 131(1), 223-232.
[http://dx.doi.org/10.1053/j.gastro.2006.04.019] [PMID: 16831604]
[42]
Chiou, J.T.; Lee, Y.C.; Huang, C.H.; Shi, Y.J.; Wang, L.J.; Chang, L.S. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. Toxicol. Appl. Pharmacol., 2020, 387114857
[http://dx.doi.org/10.1016/j.taap.2019.114857] [PMID: 31837377]
[43]
Cheng, Y.C.; Liou, J.P.; Kuo, C.C.; Lai, W.Y.; Shih, K.H.; Chang, C.Y.; Pan, W.Y.; Tseng, J.T.; Chang, J.Y. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Cancer Ther., 2013, 12(7), 1202-1212.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0778] [PMID: 23619299]
[44]
Meisner, N.C.; Hintersteiner, M.; Mueller, K.; Bauer, R.; Seifert, J.M.; Naegeli, H.U.; Ottl, J.; Oberer, L.; Guenat, C.; Moss, S.; Harrer, N.; Woisetschlaeger, M.; Buehler, C.; Uhl, V.; Auer, M. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat. Chem. Biol., 2007, 3(8), 508-515.
[http://dx.doi.org/10.1038/nchembio.2007.14] [PMID: 17632515]
[45]
Hostetter, C.; Licata, L.A.; Witkiewicz, A.; Costantino, C.L.; Yeo, C.J.; Brody, J.R.; Keen, J.C. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol. Ther.,, 2008, 7(9), 1496-1506.
[http://dx.doi.org/10.4161/cbt.7.9.6490] [PMID: 18769129]
[46]
Pryzbylkowski, P.; Obajimi, O.; Keen, J.C. Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res. Treat., 2008, 111(1), 15-25.
[http://dx.doi.org/10.1007/s10549-007-9751-0] [PMID: 17891453]
[47]
Lee, J.Y.; Chung, T.W.; Choi, H.J.; Lee, C.H.; Eun, J.S.; Han, Y.T.; Choi, J.Y.; Kim, S.Y.; Han, C.W.; Jeong, H.S.; Ha, K.T. A novel cantharidin analog N-benzylcantharidinamide reduces the expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic translocation of HuR. Biochem. Biophys. Res. Commun., 2014, 447(2), 371-377.
[http://dx.doi.org/10.1016/j.bbrc.2014.04.035] [PMID: 24735540]
[48]
Sun, L.; Zhang, S.; Jiang, Z.; Huang, X.; Wang, T.; Huang, X.; Li, H.; Zhang, L. Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-α-treated A549 cells. Biochem. Biophys. Res. Commun., 2011, 416(1-2), 99-105.
[http://dx.doi.org/10.1016/j.bbrc.2011.11.004] [PMID: 22093832]
[49]
Mutka, S.C.; Yang, W.Q.; Dong, S.D.; Ward, S.L.; Craig, D.A.; Timmermans, P.B.M.W.M.; Murli, S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res., 2009, 69(2), 510-517.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0858] [PMID: 19147564]
[50]
Doller, A.; Badawi, A.; Schmid, T.; Brauss, T.; Pleli, T.; zu Heringdorf, D.M.; Piiper, A.; Pfeilschifter, J.; Eberhardt, W. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp. Cell Res., 2015, 330(1), 66-80.
[http://dx.doi.org/10.1016/j.yexcr.2014.09.010] [PMID: 25240929]
[51]
Gabai, V.L.; Meng, L.; Kim, G.; Mills, T.A.; Benjamin, I.J.; Sherman, M.Y. Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol. Cell. Biol., 2012, 32(5), 929-940.
[http://dx.doi.org/10.1128/MCB.05921-11] [PMID: 22215620]
[52]
Xu, F.; Zhang, X.; Lei, Y.; Liu, X.; Liu, Z.; Tong, T.; Wang, W. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J. Cell. Biochem., 2010, 111(3), 727-734.
[http://dx.doi.org/10.1002/jcb.22762] [PMID: 20626035]
[53]
Lal, P.; Cerofolini, L.; D’Agostino, V.G.; Zucal, C.; Fuccio, C.; Bonomo, I.; Dassi, E.; Giuntini, S.; Di Maio, D.; Vishwakarma, V.; Preet, R.; Williams, S.N.; Fairlamb, M.S.; Munk, R.; Lehrmann, E.; Abdelmohsen, K.; Elezgarai, S.R.; Luchinat, C.; Novellino, E.; Quattrone, A.; Biasini, E.; Manzoni, L.; Gorospe, M.; Dixon, D.A.; Seneci, P.; Marinelli, L.; Fragai, M.; Provenzani, A. Regulation of HuR structure and function by dihydrotanshinone-I. Nucleic Acids Res., 2017, 45(16), 9514-9527.
[http://dx.doi.org/10.1093/nar/gkx623] [PMID: 28934484]
[54]
Muralidharan, R.; Mehta, M.; Ahmed, R.; Roy, S.; Xu, L.; Aubé, J.; Chen, A.; Zhao, Y.D.; Herman, T.; Ramesh, R.; Munshi, A. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci. Rep., 2017, 7(1), 9694.
[http://dx.doi.org/10.1038/s41598-017-07787-4] [PMID: 28855578]
[55]
Kaur, K.; Wu, X.; Fields, J.K.; Johnson, D.K.; Lan, L.; Pratt, M.; Somoza, A.D.; Wang, C.C.C.; Karanicolas, J.; Oakley, B.R.; Xu, L.; De Guzman, R.N. The fungal natural product azaphilone-9 binds to HuR and inhibits HuR-RNA interaction in vitro. PLoS One, 2017, 12(4)
[http://dx.doi.org/10.1371/journal.pone.0175471]
[56]
D’Agostino, V.G.; Adami, V.; Provenzani, A. A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. PLoS One, 2013, 8(8)e72426
[http://dx.doi.org/10.1371/journal.pone.0072426] [PMID: 23951323]
[57]
Kakuguchi, W.; Nomura, T.; Kitamura, T.; Otsuguro, S.; Matsushita, K.; Sakaitani, M.; Maenaka, K.; Tei, K. Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells. Cancer Med., 2018, 7(12), 6269-6280.
[http://dx.doi.org/10.1002/cam4.1877] [PMID: 30449075]
[58]
Wang, Z.; Bhattacharya, A.; Ivanov, D.N. Identification of Small-Molecule Inhibitors of the HuR/RNA Interaction Using a Fluorescence Polarization Screening Assay Followed by NMR Validation. PLoS One, 2015, 10(9)e0138780
[http://dx.doi.org/10.1371/journal.pone.0138780] [PMID: 26390015]
[59]
Wu, X.; Lan, L.; Wilson, D.M.; Marquez, R.T.; Tsao, W.C.; Gao, P.; Roy, A.; Turner, B.A.; McDonald, P.; Tunge, J.A.; Rogers, S.A.; Dixon, D.A.; Aubé, J.; Xu, L. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem. Biol., 2015, 10(6), 1476-1484.
[http://dx.doi.org/10.1021/cb500851u] [PMID: 25750985]
[60]
Sun, D.Q.; Wang, Y.; Liu, D.G. Cancer cell growth suppression by a 62nt AU-rich RNA from C/EBPβ 3'UTR through competitive binding with HuR. Biochem. Biophys. Res. Commun., 2012, 426(1), 122-128.
[http://dx.doi.org/10.1016/j.bbrc.2012.08.049] [PMID: 22921787]
[61]
Manzoni, L.; Zucal, C.; Maio, D.D.; D’Agostino, V.G.; Thongon, N.; Bonomo, I.; Lal, P.; Miceli, M.; Baj, V.; Brambilla, M.; Cerofolini, L.; Elezgarai, S.; Biasini, E.; Luchinat, C.; Novellino, E.; Fragai, M.; Marinelli, L.; Provenzani, A.; Seneci, P. Interfering with HuR-RNA Interaction: Design, synthesis and biological characterization of tanshinone mimics as novel, effective hur inhibitors. J. Med. Chem., 2018, 61(4), 1483-1498.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01176] [PMID: 29313684]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy